Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom. [PDF]
Hudson RDA +4 more
europepmc +1 more source
Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner. [PDF]
Paes BA +4 more
europepmc +1 more source
Challenges in the prophylaxis of severe respiratory syncytial virus infections. [PDF]
Feitosa DC, Vieira SE.
europepmc +1 more source
Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. [PDF]
Tonetto S +10 more
europepmc +1 more source
Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants. [PDF]
Bini C +10 more
europepmc +1 more source
Direct Out-of-Pocket Costs of Nirsevimab <i>vs.</i> Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis. [PDF]
Yun KW, Kang D.
europepmc +1 more source
Respiratory syncytial virus - from discovery to vaccines. [PDF]
López EL, Ferolla FM, Acosta PL.
europepmc +1 more source
Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study. [PDF]
Gil-Prieto R +8 more
europepmc +1 more source
Addressing immunization gaps in children with congenital heart disease - a narrative review. [PDF]
Jecan-Toader D, Filip C, Căinap SS.
europepmc +1 more source

